According to the International Agency for Research on Cancer, colorectal cancer is the third most common cancer in men and the second most common cancer in women worldwide. In observance of colorectal cancer awareness this month, we would like to reaffirm our commitment to helping colorectal cancer patients by increasing the adoption of the Guardant360® liquid biopsy test in clinical practice in Asia, Middle East and Africa.

Visit us online @ guardanthealthamea.com

to find out more about Guardant360®, the global leader in liquid biopsy. If you have any queries, send us an email at clientservices@guardantamea.com or contact us on WhatsApp: +65 8940 0360.

Guardant360®. Test. Take Action.